News

Shionogi Presents COVID-19 Therapeutic Agent Results at the ISIRV-WHO Virtual Conference

Notice Regarding the Progress of Phase 2/3 Clinical Trial for New Formulation of COVID-19 Recombinant Protein-based Vaccine

Shionogi and Hitachi Conclude a Memorandum of Understanding (MOU) for the Medium- to Long-Term Strategic Partnership for Shionogi Group IT Operations

Transcript for R&D Meeting

Notice on the Selection to Apply to New Market Segment “Prime Market” on the Tokyo Stock Exchange

Presentation Material for R&D Meeting

SHIONOGI announces out-licensing agreement with ViiV Healthcare to develop third-generation HIV integrase inhibitor, S-365598, with potential for ultra long-acting dosing intervals

Notice Regarding the Initiation of a Phase 2/3 Clinical Trial for a COVID-19 Therapeutic Agent in Japan

SHIONOGI Announces Agreement with AVITA for a Capital and Business Alliance

Notice Regarding the Progress of Phase 1/2 Clinical Trial for New Formulation of COVID-19 Recombinant Protein-based Vaccine

Shionogi Selected for the Global ESG Investment Index 'FTSE4Good Index Series' and 'FTSE Blossom Japan Index', for the second consecutive year.

Transcript of 1st Quarter of Fiscal 2021 Financial Results Conference Call

Shionogi Completes the First Term of the Mother to Mother Project in Illaramatak, Narok County, Kenya with Transfer of a Health Facility to the County Government

Financial Results for the First Quarter of FY2021

Presentation Material for FY2021 First Quarter Conference call

Technology Transfer for Manufacturing of COVID-19 Recombinant Protein-based Vaccine to Vietnam

Notice Regarding the Initiation of a Phase 1 Clinical Trial for a COVID-19 Therapeutic Agent in Japan

Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Shionogi and HanaVax Enter into a License Agreement for COVID-19 Vaccine Development Using Cationic Nanogel Delivery System

About a Phase III Clinical Study of Cancer-Specific Peptide Vaccine S-588410 in Patients with Esophageal Cancer

GARDP, CHAI and Shionogi announce MOU to increase access to antibiotic to treat antimicrobial resistant infections in low- and middle-income countries

SHIONOGI ANNOUNCES IN VITRO AND REAL-WORLD DATA PRESENTED AT ECCMID 2021 DEMONSTRATING ACTIVITY OF CEFIDEROCOL AGAINST CRITICAL PRIORITY GRAM-NEGATIVE BACTERIAL PATHOGENS

Shionogi selected as a member of the “SOMPO Sustainability Index” for the 10th consecutive year

Ping An-Shionogi Initiated a New Collaboration with Ping An-Health for Real World Data (RWD) Collection and Analysis Research

Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone for the Treatment of Major Depressive Disorders

SHIONOGI Announces the Start of the Wastewater Epidemiological Surveillance Service for the Novel Coronavirus in Japan

Notice Regarding an Exclusive license Agreement for a Sensitive Virus Detection Method of Viruses and Bacteria, Including Novel Coronavirus, between Hokkaido University and SHIONOGI

Th2 Chemokine TARC Kit "HISCL® TARC Assay Kit" is Approved for an Additional Indication as an Auxiliary for Assessment of COVID-19 Aggravation risk

Sign a MoU with World Anti-Doping Agency (WADA) to Prevent Misuse and Abuse of Medicines for Doping in Sports

SHIONOGI’s Greenhouse Gas Reduction Target Approved by “Science Based Targets (SBT) Initiative”

Notice Regarding the Signing of Basic Agreement of Business Partnership between SHIMADZU and SHIONOGI for Wastewater Surveillance for Viruses in the Field of Infectious Diseases, Including Novel Coronavirus

Shionogi Announces Corporate Reorganization and Personnel Reassignment

“Notice of Convocation of the 156th Annual General Meeting of Shareholders” and “Items Disclosed on Internet Concerning Notice of Convocation of the 156th Annual General Meeting of Shareholders”

Shionogi Announces Novel Coronavirus Antigen test agent “LumiraDx SARS-CoV-2 Ag Test Strip” and diagnostic instrument launched in Japan

Transcript for FY2020 Financial Results

Financial Results, Supplement, and Presentation Material for FY2020

Judgment of the Complaint for the Rescission of Tax Reassessment by the Osaka Regional Taxation Bureau

Position and Policy Regarding Reduction of the Investment Unit

Shionogi and InveniAI initiate a research collaboration agreement aimed for AI-powered multi-target drug discovery collaboration

Notice of Revisions to Dividend Forecasts
(Divident Increase)

Shionogi Filed the Application for Marketing Approval of Th2 Chemokine TARC Kit "HISCL® TARC reagent" to Assist in Predicting the Exacerbation of COVID-19

Shionogi Participated in Japan Climate Initiative (JCI) and Supports JCI Statement

Shionogi Announces Agreement of Joint Sales with LumiraDx Japan Co., Ltd. for Novel Coronavirus Antigen test agent “LumiraDx SARS-CoV-2 Ag Test Strip” and diagnostic instrument in Japan

Wastewater surveillance to monitor COVID-19 starts in Osaka Prefecture

Shionogi Announces Personnel Reassignment

Notice Regarding the Status and Completion of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Notice regarding an initiation of Phase 2 clinical trial by BioAge aimed at treating older patients of COVID-19

Establishing an Automated System for the Analysis of SARS-CoV-2 in Wastewater

Shionogi Certified as Health and Productivity Management Organization 2021 for Fifth Consecutive Year

Shionogi has been Selected as one of the "Excellent Integrated Reports" by the GPIF's Domestic Equity Managers

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Shionogi Announces Corporate Reorganization and Personnel Reassignment

Dispatch employees to health centers in areas where new coronavirus infections have spread

Shionogi wins the “Environmental Report Excellence Award” for its Integrated Report/Environment Report at the “Environmental Communication Awards”

Shionogi has been recognized for “Leaderboard” in the “Supplier Engagement Leaderboard (Climate Change)”
by CDP

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Transcript for FY2020 3Q Financial Results

Financial Results for the Third Quarter of FY2020

Presentation Material for FY2020 Third Quarter Conference call

Shionogi and BioAge conclude a license agreement aimed at treating COVID-19

Shionogi Announces European Commission Approval of XOFLUZA® (Baloxavir Marboxil) for the Treatment and Post-Exposure Prophylaxis of Influenza Virus Infection

Shionogi Announces Approval of XOFLUZA® (Baloxavir Marboxil) in Taiwan for the Post-Exposure Prophylaxis of Influenza Virus Infection

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)